My name is Dr. Christie Teigland, but people call me Dr. Christie Teigland. Here is my homepage: . I live in United States and work as an Ph.D. at

Healthcare Conferences by Healthcare Compliance Experts & Medical Coding Veterans!

Dr. Christie Teigland - Long Term Care Expert

Dr. Christie Teigland - Ph.D.

Long Term Care, Minimum Data Set (MDS) 3.0

Dr. Christie Teigland has specialized in long term care quality measurement research for the past 10 years. She has served as Principal Investigator for six large outcome studies, including a 4-year patient safety project funded by DHHS (AHRQ) that developed innovative predictive risk reports for falls and pressure ulcers.

In 2005, DHHS (HRSA) awarded Dr. Teigland a large nurse education grant to develop online education modules to provide much needed training in the new ‘nursing informatics’ skills now essential to support complex clinical decision making, including how to use computerized patient data to improve resident outcomes and quality of care. She serves on several CMS expert panels including the MDS 3.0 Validation Panel evaluating changes to the Minimum Data Set, RAND panel to identify national patient safety indicators, and AHRQ panel to develop a national patient safety culture survey for long term care.

Dr. Teigland has been conducting research on antipsychotic use in the dementia population since 2004 when she was principal investigator for a study funded by Bristol-Myers Squibb. She has presented research findings at the American Psychiatric Association Annual Meeting (2007); 15th Annual Alzheimer’s Association Dementia Care Conference (2007); the Gerontological Society Association 60th Annual Scientific Meeting (2007), and the American Medical Director’s Association Annual Meeting (2008).

She worked closely with Wall Street Journal Reporter Lucette Lagnado on a page 1 Wall Street Journal article published Dec. 4, 2007 “Prescription Abuse Seen in U.S. Nursing Homes” which quoted Dr. Teigland and incorporated data from her research.

Dr. Teigland continues to work to evaluate the overuse of antipsychotics in the frail elderly nursing home population and is currently incorporating new quality measures into an informatics software tool that will provide better information about the degree of off-label use of these medications. The current research is funded by a grant from the national Alzheimer’s Association to develop quality of life measures for dementia and Alzheimer’s residents.

Join Our Speaker Panel

Looking for Speakers in Healthcare, Pharma & Biotech.

Upcoming Webinars